StockData
Viridian Therapeutics, Inc.\DE logo

Viridian Therapeutics, Inc.\DE (VRDN) stock

VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)

Close on Nov 18, 2026Market cap $3.41BP/E –Yield –

Viridian Therapeutics, Inc.\DE enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Viridian Therapeutics, Inc.\DE's enterprise value was $2.56B on Nov 11, 2026, against $2.16B a year earlier. Over the last 5 years it ranged from $101.40M to $2.56B, with a median of $585.67M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$2.56B+22.4%
2025Dec 31, 2025$2.09B+166.0%
2024Dec 31, 2024$785.23M+22.9%
2023Dec 29, 2023$638.81M-14.2%
2022Dec 30, 2022$744.24M+339.7%
2021Dec 31, 2021$169.28M+362.0%
2020Dec 31, 2020$36.64M–
2019Dec 31, 2019-$13.58M-142.7%
2018Dec 31, 2018$31.81M-83.0%
2017Dec 29, 2017$186.85M–
2016Dec 30, 2016-$20.99M–
2015Dec 31, 2015-$4.17M–
2014Dec 31, 2014-$5.65M–

More Viridian Therapeutics, Inc.\DE figures

See a number that looks wrong?